Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


29.10.2018

2 Am J Dermatopathol
1 Arch Pathol Lab Med
1 BMC Cancer
1 Br J Dermatol
2 Eur J Dermatol
3 J Am Acad Dermatol
1 J Cell Physiol
2 J Clin Oncol
1 Lancet Oncol
2 Melanoma Res
3 Nat Med
1 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Dermatopathol

  1. STICCO KL, Feiner A, Chen S
    Melanocytic Nevus Does Not Metastasize!
    Am J Dermatopathol. 2018;40:630.
    PubMed     Text format    

  2. HELM TN, Helm KF
    Spitz Nevus Intermingling With Hemangioma, Angiomatoid Spitz Nevus, Angiotropism, and Vascular Co-option Viewed With Differing Availability Heuristics.
    Am J Dermatopathol. 2018;40:465-467.
    PubMed     Text format    


    Arch Pathol Lab Med

  3. LEE JJ, Lian CG
    Molecular Testing for Cutaneous Melanoma: An Update and Review.
    Arch Pathol Lab Med. 2018 Oct 24. doi: 10.5858/arpa.2018-0038.
    PubMed     Text format     Abstract available


    BMC Cancer

  4. KHONG B, Lawson BO, Ma J, McGovern C, et al
    Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2.
    BMC Cancer. 2018;18:1007.
    PubMed     Text format     Abstract available


    Br J Dermatol

  5. VERYKIOU S, Alexander M, Edwards N, Plummer R, et al
    Harnessing autophagy to overcome MEK-inhibitor induced resistance in metastatic melanoma.
    Br J Dermatol. 2018 Oct 19. doi: 10.1111/bjd.17333.
    PubMed     Text format     Abstract available


    Eur J Dermatol

  6. SOARES AM, Szejnfeld VL, Enokihara MY, Michalany N, et al
    High serum 25-hydroxyvitamin D concentration in patients with a recent diagnosis of non-melanoma skin cancer: a case-control study.
    Eur J Dermatol. 2018 Oct 23. pii: ejd.2018.3401. doi: 10.1684/ejd.2018.3401.
    PubMed     Text format     Abstract available

  7. DE CASTRO ARAUJO BL, Santos Thuler LC, De Melo AC
    Prognostic impact of tumescent local anaesthesia on survival and recurrence of melanoma following lymphadenectomy.
    Eur J Dermatol. 2018 Oct 23. pii: ejd.2018.3414. doi: 10.1684/ejd.2018.3414.
    PubMed     Text format    


    J Am Acad Dermatol

  8. CHERAGHLOU S, Agogo GO, Girardi M
    Treatment of primary non-metastatic melanoma at high-volume academic facilities is associated with improved long-term patient survival.
    J Am Acad Dermatol. 2018 Oct 23. pii: S0190-9622(18)32760.
    PubMed     Text format     Abstract available

  9. VASICEK B, Erickson T, Lake E
    In Response to "Descriptive Survival Study of Nail Melanoma Patients Treated With Functional Surgery vs Distal Amputation".
    J Am Acad Dermatol. 2018 Oct 22. pii: S0190-9622(18)32751.
    PubMed     Text format    

  10. BOOZALIS E, Shah AA, Wigley F, Kang S, et al
    Morphea and systemic sclerosis are associated with an increased risk of melanoma and non-melanoma skin cancer.
    J Am Acad Dermatol. 2018 Oct 20. pii: S0190-9622(18)32755.
    PubMed     Text format    


    J Cell Physiol

  11. MOHAMMADPOUR A, Derakhshan M, Darabi H, Hedayat P, et al
    Melanoma: Where we are and where we go.
    J Cell Physiol. 2018 Oct 26. doi: 10.1002/jcp.27286.
    PubMed     Text format     Abstract available


    J Clin Oncol

  12. DAVAR D, Wang H, Chauvin JM, Pagliano O, et al
    Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma.
    J Clin Oncol. 2018 Oct 25:JCO1800632. doi: 10.1200/JCO.18.00632.
    PubMed     Text format     Abstract available

  13. HAUSCHILD A, Dummer R, Schadendorf D, Santinami M, et al
    Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma.
    J Clin Oncol. 2018 Oct 22:JCO1801219. doi: 10.1200/JCO.18.01219.
    PubMed     Text format     Abstract available


    Lancet Oncol

  14. HODI FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, et al
    Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Lancet Oncol. 2018 Oct 18. pii: S1470-2045(18)30700.
    PubMed     Text format     Abstract available


    Melanoma Res

  15. ABDEL-RAHMAN O
    Population-based validation of the National Cancer Comprehensive Network recommendations for baseline imaging workup of cutaneous melanoma.
    Melanoma Res. 2018 Oct 22. doi: 10.1097/CMR.0000000000000528.
    PubMed     Text format     Abstract available

  16. MARCOVAL J, Sabate-Llobera A, Bermejo J, Fornons-Servent R, et al
    Hibernoma as an incidental finding in the 18F-FDG PET/CT of a patient with melanoma.
    Melanoma Res. 2018 Oct 24. doi: 10.1097/CMR.0000000000000530.
    PubMed     Text format     Abstract available


    Nat Med

  17. AMARIA RN, Reddy SM, Tawbi HA, Davies MA, et al
    Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
    Nat Med. 2018 Oct 25. pii: 10.1038/s41591-018-0252.
    PubMed     Text format     Abstract available

  18. AMARIA RN, Reddy SM, Tawbi HA, Davies MA, et al
    Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.
    Nat Med. 2018 Oct 25. pii: 10.1038/s41591-018-0251.
    PubMed     Text format     Abstract available

  19. AUSLANDER N, Zhang G, Lee JS, Frederick DT, et al
    Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma.
    Nat Med. 2018 Oct 17. pii: 10.1038/s41591-018-0247.
    PubMed     Text format     Abstract available


    PLoS One

  20. WIKSTROM JD, Lundeberg L, Frohm-Nilsson M, Girnita A, et al
    Differences in cutaneous melanoma treatment and patient satisfaction.
    PLoS One. 2018;13:e0205517.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: